OrsoMedical

Privacy Policy

Last Updated: May 15, 2026

1. Introduction

OrsoMedical ("we," "us," or "our") operates a fee-for-service medical information platform that provides AI-generated health information with optional licensed physician review. This Privacy Policy explains how we collect, use, disclose, and safeguard your information when you use our services.

IMPORTANT: Our service is designed for de-identified, anonymous health questions only. You should NOT submit any personally identifiable health information (PHI) or protected health information.

2. Information We Collect

2.1 Information You Provide

  • Account Information: Email address and password when you create an account.
  • Health Questions: The medical questions you submit through our platform. These should be de-identified and contain no personal health information.
  • Payment Information: When you purchase services, payment is processed through Stripe. We do not store your full credit card information.

2.2 Information Automatically Collected

  • Device and browser information
  • IP address (anonymized)
  • Usage data and interaction with our services
  • Cookies and similar tracking technologies

3. De-Identified Questions Policy

Critical Privacy Requirement

You must NOT include any of the following in your questions:

  • Names (yours or others)
  • Dates of birth or ages that could identify you
  • Addresses or location information
  • Phone numbers or email addresses
  • Medical record numbers
  • Social Security numbers
  • Insurance information
  • Any other personally identifiable information

By submitting a question, you certify that it contains no personally identifiable information. If we identify PHI in your submission, we reserve the right to delete the question without refund.

4. How We Use Your Information

  • To provide and maintain our services
  • To process your questions and generate AI responses
  • To facilitate physician review of questions (for paid services)
  • To process payments and send transaction confirmations
  • To communicate with you about your account or services
  • To improve and optimize our services
  • To comply with legal obligations

5. AI Processing

Your de-identified questions are processed by artificial intelligence systems to generate initial responses. These AI systems are trained on medical literature and general health information. AI responses are:

  • Generated automatically based on your question
  • Not reviewed by a physician unless you purchase a physician review service
  • For educational and informational purposes only
  • Not a substitute for professional medical advice

6. Data Sharing and Disclosure

We may share your information with:

  • Service Providers: Third parties that help us operate our services (payment processors, hosting providers, AI services)
  • Physicians: Licensed physicians who review questions (for paid physician review services)
  • Legal Requirements: When required by law or to protect our rights

We do NOT sell your personal information to third parties.

7. Data Security

We implement appropriate technical and organizational measures to protect your information, including:

  • Encryption of data in transit and at rest
  • Secure authentication systems
  • Regular security assessments
  • Limited access to personal information

8. Data Retention

We retain your information for as long as necessary to provide our services and comply with legal obligations. De-identified questions and responses may be retained indefinitely for service improvement purposes. You may request deletion of your account and associated data by contacting us.

9. Your Rights

Depending on your location, you may have the right to:

  • Access your personal information
  • Correct inaccurate information
  • Delete your information
  • Opt out of certain data uses
  • Data portability

10. HIPAA Notice

OrsoMedical is NOT a covered entity under HIPAA. Our service is designed for de-identified, educational health questions only. We do not provide medical treatment, diagnose conditions, or maintain medical records. No doctor-patient relationship is created through use of our services.

11. Contact Us

If you have questions about this Privacy Policy or our data practices, please contact us at:

OrsoMedical
Email: privacy@orsomedical.com

12. Changes to This Policy

We may update this Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page and updating the "Last Updated" date.

Latest
GLP-1 Agonists: 72-Week Lean Mass Data Confirms Leucine Protocol Necessity · NEJMAshwagandha KSM-66: 600mg/day Optimal Dose Confirmed — 24-RCT Meta-Analysis · Examine.comFerrous Bisglycinate vs. Sulfate: Equivalent Iron, Fewer GI Events — Head-to-Head RCT · ASHLion's Mane 1–2g/day Significantly Improves Cognitive Scores: 8-RCT Systematic Review · PubMedNMN 500mg Phase II Trial: NAD+ Increase + Improved Muscle Strength in Adults 65–80 · NEJMResistance Training 3×/Week + Leucine Reduces Sarcopenia Risk 60% During GLP-1 Use · ACSMSage Leaf Extract: 50% Hot Flash Reduction Confirmed — ACP Meta-AnalysisBerberine 1000–1500mg Comparable to Metformin 500mg BID for Pre-Diabetes · ACP JournalsVitamin D >40ng/mL Significantly Correlates with Higher Free Testosterone in Men · NIH ODSFisetin as Senolytic: First Human Dose-Escalation Study Shows Safe Cellular Clearance · PubMedGLP-1 Agonists: 72-Week Lean Mass Data Confirms Leucine Protocol Necessity · NEJMAshwagandha KSM-66: 600mg/day Optimal Dose Confirmed — 24-RCT Meta-Analysis · Examine.comFerrous Bisglycinate vs. Sulfate: Equivalent Iron, Fewer GI Events — Head-to-Head RCT · ASHLion's Mane 1–2g/day Significantly Improves Cognitive Scores: 8-RCT Systematic Review · PubMedNMN 500mg Phase II Trial: NAD+ Increase + Improved Muscle Strength in Adults 65–80 · NEJMResistance Training 3×/Week + Leucine Reduces Sarcopenia Risk 60% During GLP-1 Use · ACSMSage Leaf Extract: 50% Hot Flash Reduction Confirmed — ACP Meta-AnalysisBerberine 1000–1500mg Comparable to Metformin 500mg BID for Pre-Diabetes · ACP JournalsVitamin D >40ng/mL Significantly Correlates with Higher Free Testosterone in Men · NIH ODSFisetin as Senolytic: First Human Dose-Escalation Study Shows Safe Cellular Clearance · PubMed